|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
Checkmate Pharmaceuticals
Aclaris Therapeutics
|
|
gptkbp:awards
|
gptkb:Nobel_Prize_in_Physiology_or_Medicine_(2018)
Best Places to Work (2021)
|
|
gptkbp:CEO
|
gptkb:Leonard_Schleifer
|
|
gptkbp:clinicalTrials
|
ongoing
Phase 3 trials
Phase 1 trials
Phase 2 trials
COVID-19 treatments
|
|
gptkbp:collaborations
|
gptkb:AstraZeneca
gptkb:Bayer_AG
gptkb:Teva_Pharmaceutical_Industries
|
|
gptkbp:employees
|
approximately 8,000
|
|
gptkbp:founded
|
1988
|
|
gptkbp:founder
|
gptkb:Leonard_Schleifer
|
|
gptkbp:headCoach
|
over 8,000 employees
|
|
gptkbp:headquarters
|
gptkb:Tarrytown,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Regeneron Pharmaceuticals
|
|
gptkbp:leadership
|
Executive Team
Board_of_Directors
|
|
gptkbp:market
|
$70 billion (2021)
|
|
gptkbp:netIncome
|
$2.5 billion (2020)
|
|
gptkbp:partnerships
|
gptkb:U.S._Department_of_Health_and_Human_Services
gptkb:National_Institutes_of_Health
Sanofi
|
|
gptkbp:philanthropy
|
gptkb:Regeneron_Foundation
|
|
gptkbp:products
|
gptkb:Regen-Cov
gptkb:Eylea
Dupixent
|
|
gptkbp:research
|
cardiology
endocrinology
neurology
oncology
rare diseases
autoimmune diseases
hematology
rheumatology
dermatology
infectious diseases
immunology
respiratory diseases
ophthalmology
transplantation
urology
gastroenterology
pulmonology
metabolic diseases
|
|
gptkbp:researchFocus
|
monoclonal antibodies
|
|
gptkbp:revenue
|
$8.5 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:REGN
|
|
gptkbp:technology
|
gptkb:Regeneron_Genetics_Center
VelociSuite
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|